Notably, the phase III DESTINY-Breast04 (DB-04) trial provided evidence that T-DXd significantly prolongs OS compared with standard chemotherapy in previously treated patients with HER2-low advanced breast cancer [39]. This evidence concerns the gene ERBB2 and breast carcinoma.